New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareP21 vs Vesilute

P21 vs Vesilute

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
P21
Anti-Aging & Longevity
Vesilute
Summary
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Half-Life
Not well characterized; likely short, but neurogenic effects persist long after administration
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Intranasal
SubQ, Oral
Research
Typical Dose
100–500 mcg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
Side Effects
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
Stacks With